The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
With an aging global population, rates of Alzheimer’s disease on the rise, high costs of care for those with dementia, and an unpromising landscape for effective drugs, questions of how to prevent or ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy ... significant unmet need for new innovative treatment options that target ...
A century ago, physics had its Darwinian moment — a change in perspective that was as consequential for the physical sciences as the theory of evolution by natural selection was for biology.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
India News Live: Stay informed with our live blog covering India’s latest in politics, economy, crime, and general news. Get real-time updates on political developments, financial trends ...